The effects of AT1R-AAs and ETAR-AAs are also described in severe acute respiratory syndrome coronavirus 2 (COVID-19), in which their titers are significantly increased in patients with an unfavorable disease course [13]. This evidence concerns the gene AGTR1 and COVID-19.